Palvella Therapeutics, Inc. Share Price & Technical Analysis
PVLA · $114.0 (-1.66%)
Healthcare / Biotechnology
$114.0
-1.66%
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cli…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, 0% avg return in past 3 year May month.
23% return in 2026, 76% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -26% | 70% | -12% | 2% | -11% | – | – | – | – | – | – | – | 23% |
| 25 | 12% | 53% | 47% | -14% | 0% | -9% | 63% | 48% | 17% | 26% | 29% | 1% | 272% |
| 24 | -1% | -12% | 8% | -23% | -14% | -7% | 73% | 16% | -5% | 4% | -5% | -27% | 8% |
| 23 | 60% | -6% | -35% | -24% | 12% | -80% | 26% | 57% | -15% | -24% | -13% | -10% | -53% |
| 22 | -5% | -16% | -2% | -8% | -36% | 3% | -7% | -19% | -21% | -4% | -13% | 6% | -123% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.77B
P/E ratio
—
52W high
$151.2
52W low
$20.20
Volume
1,46,366
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Palvella Therapeutics, Inc. share price today?
- Palvella Therapeutics, Inc. (PVLA) last traded around $114.0 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PVLA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PVLA. Download the app for real-time alerts.
- How can I analyze Palvella Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.